- Home
- CBRL vs OMER Comparison
CBRL vs OMER Comparison
Compare CBRL & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBRL | OMER |
|---|---|---|
| Founded | 1969 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1998 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CBRL | OMER |
|---|---|---|
| Price | $66.89 | $17.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $50.71 | $27.50 |
| AVG Volume (30 Days) | 846.3K | ★ 1.1M |
| Earning Date | 12-08-2026 | 11-20-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ 1.40 | 0.77 |
| Revenue | ★ $3,030,445,000.00 | $29,868,000.00 |
| Revenue This Year | $1.72 | N/A |
| Revenue Next Year | $2.28 | $73.59 |
| P/E Ratio | $46.43 | ★ $21.79 |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $24.85 | $6.24 |
| 52 Week High | $73.67 | $21.24 |
Technical Indicators
Market Signals| Indicator | CBRL | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 48.14 |
| Support Level | $28.43 | $16.17 |
| Resistance Level | $70.28 | $19.68 |
| Average True Range (ATR) | 2.84 | 0.86 |
| MACD | -0.83 | -0.01 |
| Stochastic Oscillator | 25.84 | 43.45 |
Price Performance
Historical ComparisonAbout CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants menu that features home-style country food and a wide variety of decorative and functional items such as rocking chairs, holiday and seasonal gifts, toys, apparel, cookware and foods.
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.